OncoSil Medical Limited Information

Oncosil Medical Ltd (ASX: OSL), formerly known as NeuroDiscovery Limited, is a North Sydney-based medical device company engaged in developing localised treatments for cancer in Australia. Its flagship product is the brachytherapy device 'OncoSil', comprising OncoSil Phosphorous-32 Microparticles and OncoSil Diluent, that implant a pre-specified dose of beta radiation emitting isotope directly into cancerous tissue for the treatment of both pancreatic and liver cancer. The OSL stock has a market capitalisation of AUD 100.91 million and last traded at a market price of AUD 0.160 with the close of the trading session on February 13th, 2019. Around 128,666 volume of shares were traded in total. The stock has generated a negative return yield of 3.03% in the last six months and also a negative YTD return of 8.57%. The company reported the net cash and cash equivalents at AUD 13.03 million at the end of the quarter ended December 31st, 2018, down from the previous quarter's AUD 16.12 million. There were major cash burns from operating activities at around AUD 3.09 million and no investing or financing initiatives during the period.